Quest Laboratories (NSE:QUESTLAB) NonCurrent Deferred Revenue: ₹0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:QUESTLAB Quest Laboratories Ltd NSE:QUESTLAB
46 GF Score
Price ₹89.70
! 5 Warning Signs
View Full Analysis

What is Quest Laboratories NonCurrent Deferred Revenue?

Quest Laboratories NSE:QUESTLAB -0.61% 46 NonCurrent Deferred Revenue is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:QUESTLAB with a GF Score™ of 46/100. The stock has 5 warning signs investors should review.

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

Quest Laboratories's non-current deferred revenue for the quarter that ended in Mar. 2026 was ₹0 Mil.

Quest Laboratories NonCurrent Deferred Revenue Related Terms

Quest Laboratories NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Quest Laboratories's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Quest Laboratories NonCurrent Deferred Revenue Chart

Quest Laboratories Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
NonCurrent Deferred Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Quest Laboratories Semi-Annual Data
Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
NonCurrent Deferred Revenue Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:QUESTLAB
46GF Score
Quest Laboratories Ltd NSE:QUESTLAB
NonCurrent Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Revenue of ₹0 Mil mean?
Quest Laboratories (NSE:QUESTLAB) has a NonCurrent Deferred Revenue of ₹0 Mil as of Mar. 2026. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Quest Laboratories and its competitors.
Is Quest Laboratories' NonCurrent Deferred Revenue too high?
Quest Laboratories' current NonCurrent Deferred Revenue is ₹0 Mil. Overall, Quest Laboratories has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Quest Laboratories' NonCurrent Deferred Revenue compare to LLY and JNJ?
Quest Laboratories' NonCurrent Deferred Revenue of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Drug Manufacturers company?
A good NonCurrent Deferred Revenue depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Quest Laboratories and its competitors. Quest Laboratories's current NonCurrent Deferred Revenue is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Laboratories stock overvalued right now?
Quest Laboratories (NSE:QUESTLAB) has a current NonCurrent Deferred Revenue of ₹0 Mil. The current NonCurrent Deferred Revenue is ₹0 Mil. Quest Laboratories' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For Quest Laboratories (NSE:QUESTLAB), the current NonCurrent Deferred Revenue is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Quest Laboratories Business Description

Address Sector III, Plot No. 45, Pithampur Industrial Area, Opposite Kissan Pipe Unit 4, District Dhar, Pithampur, Dhar, MP, IND, 454775
Quest Laboratories Ltd is engaged in the business of manufacturing pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. It produces various products, comprising ethical drugs, generic drugs, and over-the-counter drugs, and is also available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids, among others. The company operates in a single segment of Drugs and Chemicals.
46GF Score

Get the complete analysis for NSE:QUESTLAB

NonCurrent Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹89.70
Price